Aublé & Associés is assisting DelleD in its €3 million fundraising with an institutional investor.
Aublé & Associés advised DelleD in its €3 million fundraising from an institutional investor.
DelleD is a French biotech company specialized in the optimization of plant production through lighting and artificial intelligence as well as in the development of cannabis-based medicines.
The company is developing with leading public and private laboratories, innovative extraction methods, genetic and production optimization of cannabis, galenic formulations and is currently conducting a pre-clinical trial in oncology. A second clinical trial will be launched in 2021.
DelleD has been in contact with the Ministry of Agriculture since 2017 to set up its research and development operations on cannabis plants and in order to install its French center of excellence in research and development for its further building of its intellectual property portfolio and providing innovative cannabis-based medical products.
Stakeholders on the operation
- Weglot advice and founders: Matthieu Aublé
- Collaborator : Thibaut Lesure
